The trajectory of Viagra presents a intricate picture for investors. While the initial introduction generated substantial returns, the end of its exclusive rights opened the avenue to generic alternatives, dramatically diminishing market share. This presents a specific dilemma for pharmaceutical companies banking on similar blockbuster offerings, s

The legacy of Viagra, and its parent company copyright, presents a complex case study for investors. At first a blockbuster drug, producing billions in income, its patent expiration created a deluge of knock-off medications, significantly diminishing its market share . While some businesses may try to capitalize on related treatments , the present